Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence

The low response rate of current cancer immunotherapy suggests the presence of few antigen-specific T cells and a high number of immunosuppressive factors in tumor microenvironment (TME). Here, we develop a syringeable immunomodulatory multidomain nanogel (iGel) that overcomes the limitation by reprogramming of the pro-tumoral TME to antitumoral immune niches. Local and extended release of immunomodulatory drugs from iGel deplete immunosuppressive cells, while inducing immunogenic cell death and increased immunogenicity. When iGel is applied as a local postsurgical treatment, both systemic antitumor immunity and a memory T cell response are generated, and the recurrence and metastasis of tumors to lungs and other organs are significantly inhibited. Reshaping of the TME using iGel also reverts non-responding groups to checkpoint blockade therapies into responding groups. The iGel is expected as an immunotherapeutic platform that can reshape immunosuppressive TMEs and synergize cancer immunotherapy with checkpoint therapies, with minimized systemic toxicity.

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection Flow cytometry data was collected using BD Accuri C6 Plus and BD FACSDiva software (v8.0.1.1). SoftMax Pro 5.0 was using for plate based absorbance data. Simple PCI 6 was used for in vivo fluorescence imaging and DeltaVision softWoRx was used for in vitro fluorescence imaging. UVProbe 2.62 was used for in vitro release data. Gatan DigitalMicrograph was used for TEM. ParaVision v5.1 was used for MRI. ELSZ-1000 was used for DLS/zeta. TRIOS software was used for rheological data.

Data analysis
Microsoft Excel and Graphpad Prism 7 were used for statistical analysis and plotting. FlowJo VX was used for flow cytometry analysis. Simple PCI 6 and ImageJ software were used to analyze fluorescent image and MNDV diameter. For MRI image analysis ParaVision v5.1 was used.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

nature research | reporting summary
October 2018 Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
Details regarding the sample size of all experiments are provided in figure legends. Sample size were estimated to achieve about 90% power for detection of significant differences in tumor volume between groups based on means and standard deviations in preliminary studies. They were consistent with sample size of previously reported results in other studies.
Data exclusions No data were excluded.

Replication
The replicated experiments were noted in the manuscript as one of x independent experiments. Experiments were repeated and experimental findings were reproducible. The conclusions derived from the data in each experiment were consistent.
Randomization For in vitro test, samples were randomly allocated to corresponding experimental groups. For in vivo test, mice were inoculated tumor at the same time and then randomly assigned to a group for similar average tumor sizes. For tumor resection procedure, the remaining tumor was precisely controlled as shown detail in method and supplementaly information. Mice were allocated randomly to each treatment group.

Blinding
Survival test, tumor volume measurement and imaging experiments to test the efficacy of each treatment groups were conducted by independent researchers who were unaware of the treatment conditions.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Validation
The antibodies for flow cytometry were validated by Biolegend using bone marrow cells or splenocytes from C57BL/6 mice, with related data shown on the manufacturer website. The validation of therapeutic antibodies were performed by SDS-PAGE by Bioxcell, with relevant data presented on the manufacturer website. Additional validation of both therapeutic and flow cytometric antibodies was not performed by the authors.

Wild animals
This study did not involve wild animals.

Field-collected samples
This study did not involve field-collected samples.

Ethics oversight
All of the animal handling and studies were conducted based on the guidelines and approval by the Institutional Animal Care and Use Committee (IACUC) of Sungkyunkwan University School of Medicine, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International) and abides by the Institute of Laboratory Animal Resources (ILAR) guide.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

nature research | reporting summary
October 2018 Flow Cytometry Plots Confirm that: The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.

Sample preparation
Tumors, spleen and tumor-draining lymph nodes were harvested from sacrificed mice. The tumors and lymph nodes were cut into small pieces and resuspended in collagenase D in DMEM (1 mg/mL). The solutions were incubated for 1 h at 37°C on a shaker (90 rpm) and then filtered through a 70-μm Falcon cell strainer. The supernatant from the digested tumor tissues was collected, centrifuged at 490 × g for 5 min, and resuspended. The spleen was mechanically dissociated and resuspended in DMEM. The suspension was filtered through a 70-μm Falcon cell strainer, centrifuged and resuspended. Erythrocytes were lysed with red blood cell lysis buffer for 5 min at 37°C. Cell suspensions were prepared as described above and then stained with the antibodies. The cells were then washed twice and analysed using flow cytometer. Gating strategy Initial cell populations were gated for a live population using FSC and SSC plot of cell only sample. The gate was set to remove cell debris and dead cells (small FSC and SSC) and large clumps or aggregates of cells (large FSC and SSC) and used across all samples. This live population was then further gated as shown in Supplementary Fig. S21.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.